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Dr Esquerdo 46, Madrid 28007, SpainThe heart and liver are organs that are closely related in both and disease. Previous cardiac conditions may inﬂuence the out-
health and disease. Patients who undergo liver transplantation
may suffer from heart disease that is: (a) related to the original
cause of the liver disease such as hemochromatosis, (b) related
to the liver disease itself, or (c) related to other associated condi-
tions. Furthermore, liver transplantation is one of the most car-
diovascular stressful events that a patient with cirrhosis may
undergo. After liver transplantation, the progression of pre-exist-
ing or the development of new-onset cardiac disease may occur.
This article reviews the relationship between the heart and liver
transplantation in the pre-transplant, intra-operative, and post-
transplant periods.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The mutual interaction between the heart and the liver in health
and disease states has been established for some time. Patients
with chronic heart failure may have liver damage, even cirrhosis,
due to liver congestion [1], while patients with liver disease have
cardiovascular abnormalities [2,3]. In patients with cirrhosis, car-
diac disease can be related to (1) systemic diseases that affect
both the heart and the liver, such as chronic excessive consump-
tion of alcohol, and hemochromatosis, (2) speciﬁc cardiac dis-
eases of cirrhosis and (3) common cardiac diseases that also
occur in general population that can inﬂuence the outcomes of
liver transplantation (LT).
LT is an important event that completely changes the natural
history of liver disease and also inﬂuences cardiac performanceJournal of Hepatology 20
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score; MRI, magnetic resonance imaging.comes of transplant, so thorough evaluation prior to LT is recom-
mended. Furthermore, the surgical procedure on its own, which
involves acute changes in loading conditions and the liberation
of cytokines and toxins associated with reperfusion, has a docu-
mented inﬂuence on heart function [4–6]. Lastly, after LT there
is an increased risk of cardiac events associated with life-long
immunosuppression and its secondary effects.
This review aims to summarize the present state of knowl-
edge regarding the interaction between the heart and the liver
in the pre-transplant period, during LT, and in the post-transplant
period, focusing speciﬁcally on patients with cirrhosis who
undergo LT due to end-stage liver disease or hepatocellular carci-
noma. Table 1 shows the most frequent cardiac conditions
including their prevalence and outcome after LT.Cardiac diseases in the pre-transplant period
Systemic diseases that can affect both the heart and the liver
Several systemic diseases that cause cirrhosis may also induce
speciﬁc cardiac diseases. The most relevant etiologies are alco-
holic disease and hemochromatosis. Non-alcoholic fatty liver dis-
ease (NAFLD) is frequently considered as a component of the
metabolic syndrome that can also lead to cardiovascular disease.
Finally, familial amyloid polyneuropathy is an infrequent sys-
temic disease that may lead to cardiac disease.
Chronic alcoholism
Excessive alcohol consumption may lead to cirrhosis and alco-
holic cardiomyopathy, which is the main cause of secondary
non-ischemic dilated cardiomyopathy in the western world
[7–9]. It is characterized by the presence of left ventricular dila-
tation, impaired systolic function, myocardial ﬁbrosis, and dis-
ruption of the myoﬁbrillary structure. Although overt alcoholic
liver disease and cardiac involvement usually do not occur
together, patients with alcoholic cirrhosis without signs or symp-
toms of heart disease may have demonstrable evidence of asymp-
tomatic myocardial disease [9]. Abstinence from alcohol in the
early stages of the cardiac disease may lead to signiﬁcant
improvement in most patients [10,11].
On the other hand, alcoholic liver cirrhosis patients may be at
increased risk of coronary artery disease (CAD). Although mild to
moderate chronic consumption of alcohol has been suggested to11 vol. 54 j 810–822
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have a protective effect, high average chronic consumption of
alcohol (as is common in patients with alcohol induced cirrhosis)
has been shown to increase the risk for CAD in comparison to tee-
totalers [12,13].
Hemocromatosis
Iron overload is associated with the deposition of iron in the
myocardium and conducting system that can lead to electrocar-
diographic abnormalities and heart failure. Although electrocar-
diographic abnormalities are frequent in patients with cirrhosis
due to hemochromatosis [14], heart failure is unusual. Increases
in left ventricular mass, end-diastolic and end-systolic diame-
ters of the left ventricle, and left atrium diameters may be
observed, as well as signiﬁcant changes of systolic function
indices. Patients without overt symptoms of heart disease
may have an augmentation of atrial contraction as an early
manifestation of abnormal diastolic function [15]. At early
stages of heart involvement, asymptomatic disease may be
unmasked by cardiac magnetic resonance imaging [16]. Func-
tional and structural cardiac changes can improve with iron
removal therapy [17,18], although it may not be feasible in
patients with decompensated cirrhosis. Patients with hemo-
chromatosis have a 14-fold increase in mortality due to heart
disease compared to an age and sex matched population [14]
and increased mortality after LT compared to other etiologies
[19,20]. Careful pre-transplant cardiac evaluation is essential
in these patients.
Non-alcoholic fatty liver disease (NAFLD)
NAFLD is associated with the metabolic syndrome, which, in turn,
is clearly associated to CAD. Several studies suggest that patients
with NAFLD have higher incidence of CAD [21–24]. However, the
association between hepatic steatosis and cardiovascular disease
has recently been questioned [25].
Familial amyloid polyneuropathy
Although familial amyloid polyneuropathy does not speciﬁcally
induce liver damage, since the enzymatic defect that leads to this
disease is found in the liver, LT is the main therapeutic approach.
One should keep in mind that this condition may induce heart
disease associated with amyloid deposition, which may lead to
cardiac denervation, restrictive cardiomyopathy, conduction dis-
turbances and death. Echocardiography and autonomic function
testing are important for the evaluation of these patients when
considering LT [26].
Cardiac abnormalities speciﬁc to cirrhosis
Hemodynamic changes in cirrhosis
Cirrhosis induces characteristic hemodynamic changes that inﬂu-
ence cardiac evaluation (Fig. 1). An increase in portal pressure
causes an intense splanchnic vasodilation, which leads to a
reduction in the systemic vascular resistance and afterload
[27,28]. Initially, this decrease can be overcome by activation of
compensatory mechanisms in order to maintain a normal central
volemia or preload. However, with further progression of the dis-
ease, these mechanisms fail, and there is a decrease not only in
afterload, but also in preload. The hemodynamic abnormalities
observed in cirrhosis progress as the liver disease progresses, so
Child-Pugh class A patients have a lesser degree of hemodynamic
derangement than Child-Pugh class C patients [28].Journal of Hepatology 201Key points Cirrhotic cardiomyopathy
In recent years, researchers have suggested that there is a speciﬁc
heart disease associated with cirrhosis, termed cirrhotic cardio-
myopathy. This condition is closely related to the hemodynamic
alterations that occur in cirrhosis and is characterized by the
presence of: (1) increased baseline cardiac output, with blunted
ventricular response to stimuli, (2) systolic and diastolic dysfunc-
tion which are best observed in stress situations, and (3) electro-
physiological abnormalities [29]. Brain natriuretic peptide has
been proposed as a marker of cirrhotic cardiomyopathy [30,31].
In patients with cirrhosis, the characteristic hemodynamic
changes associated with portal hypertension previously
described [27,28] make the accurate evaluation of heart function
very difﬁcult. Standard echocardiographic indices of systolic and
diastolic function are deeply affected by changes in load [32,33].
Therefore, in the context of cirrhosis, interpretation of these
imaging tests can be challenging, because of the progressive
hemodynamic changes that lead to different loading conditions.
However, there is evidence that supports that patients with
end-stage liver disease have an impaired cardiac function. Abnor-
mal cardiac function is more easily observed in stress situations
such as LT [34], TIPS placement [35], and infections like sponta-
neous bacterial peritonitis [36]. It is also hypothesized that hepa-
torenal syndrome may be a manifestation of cardiac impairment,
causing the organ to deliver insufﬁcient perfusion to the kidney
[37–40].
A prolonged QT interval is an easily evaluated electrophysio-
logical abnormality associated with cirrhotic cardiomyopathy. It
has been related to the severity of the liver disease and the
degree of portal hypertension [41–44] and mortality [41,45].1 vol. 54 j 810–822 811
Table 1. Relationship between different cardiac diseases present previous to LT and outcome after LT. ⁄Post-transplant outcome also depends on management of the
primary cause of liver disease. Data regarding mortality is orientative, as multiple factors are likely to be involved. No information regarding relationship between LT and
cardiac arrythmias, or alcoholic cardiomyopathy has been reported. No data was available regarding prevalence of alcoholic cardiomyopathy in liver transplant candidates
nor its effect on LT.
Coronary artery disease  
Valvular heart disease  
Asymptomatic patent foramen ovale 
Cirrhotic Cardiomyopathy  
increased baseline CO 
chronotropic abnormalities 
systolic and diastolic dysfunction
Portopulmonary hypertension  
Mortality 50%
Morbidity among survivors 81% [136]
MPAP >50mmHg 100% mortality 
MPAP 35-50mmHg 50% mortality 
MPAP <35 mmHg no disease related increase in mortality [57]
Specific cardiac disease
hemocromatosis* 
 amyloidosis 
During Transplant
Valvular dysfunction associated to
greater vasoactive drug and blood 
transfusion requirements [83]
Non significant trend to greater 
incidence of reperfusion syndrome [82]
23% abnormal cardiac response [6] 
evitarepoartnidetacilpmoC
management [19] [19, 20, 140]
Post-transplant
Valvular dysfunction 
Longer stay in ICU, 
no difference in morbidity or mortality [82] 
- 3.3-7% severe left heart failure [34, 87]
- 45% mortality in those with severe left heart failure [127]
- Progressive improvement of all abnormalities, although 
possible initial worsening of diastolic function [40, 50, 132] 
- 15-25% of deaths caused by cardiac events in post LT
- No improvement of sympathetic cardiac denervation, 
progression of cardiac amyloid infiltration [26, 128, 129] 
no differences in mortality rates [83]
tnalpsnarterP
Prevalence 6-26% [68-70] 
27.5% valvular dysfunction [83]  
 Prevalence 4% [82]  
Greater prevalence with 
40-90% prevalence prolonged cQT 
[41, 46, 149] 
Prevalence 2-14% [52-56] 
 EKG abnormalities 46% [14]  
more severe disease
Frontiers in Liver TransplantationHowever, sudden death is not a frequent event in patients with
cirrhosis despite 60% of Child-Pugh class C patients have a pro-
longed QT interval [41]. Interestingly, it has also been associatedCentral hypovo
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Fig. 1. Diagram of pathophysiology of portal hypertension. The increase in portal pres
ﬂow. In cirrhosis there is an initial increase in intrahepatic resistance. This increase in int
hypovolemia and activation of vasoactive mechanisms that increase cardiac output an
combination of both mechanisms leads to an increase in portal pressure. Furthermore,
sodium retention and further increases portal venous ﬂow.
812 Journal of Hepatology 201to survival in Child-Pugh class A patients [41], and has been
more frequently observed in patients who died after LT than in
survivors [46]. Special care should be taken with drugs that canlemia 
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sure is deﬁned by Ohm’s law, that states that pressure depends on resistance and
rahepatic resistance leads to splanchnic vasodilation which in turn leads to central
d kidney sodium retention. This leads to an increase in portal venous ﬂow. The
increased intrahepatic resistance also leads to an independent increase in kidney
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prolong ventricular repolarization, i.e. anti-arrythmics such as
amiodarone, or antibiotics such as erythromycin [47]. Use of
betablockers has been associated to shortening of the QT interval
[48,49], a ﬁnding which may partly explain the low incidence of
sudden death in this population.Table 2. Summary of abnormalities associated cirrhotic cardiomyopathy in baseline a
stress. (See below-mentioned references for further information.)
CO: cardiac output
CI: cardiac index
SV: stroke volume
SVI: stroke volume index
PWCP: pulmonary wedged capillary pressure
LVEDV: left ventricle end diastolic volume
LVESVI: left ventricle end systolic volume index
LVEF: Left ventricle ejection fraction
LVWT: left ventricle wall thickness
LVEDP: left ventricle end diastolic pressure
IVRT: isovolumetric relaxation time
DT: deceleration time
PFR: peak ﬁlling rate
LF/HF: low frequency/high frequency heart rate ratio
QTc: corrected QT interval
Journal of Hepatology 201A more detailed description of the abnormalities associated
with cirrhotic cardiomyopathy is shown in Table 2. Although
there have been reports suggesting that alterations in cardiac
structure associated with cirrhotic cardiomyopathy may be mod-
iﬁable with pharmacological treatment [50,51], further studiesnd in stress conditions with modiﬁcation only of preload or afterload or mixed
1 vol. 54 j 810–822 813
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are needed. Further insight on cirrhotic cardiomyopathy is
offered in a recently published review [29].
Portopulmonary hypertension
Portopulmonary hypertension is a liver disease-speciﬁc cause of
primary pulmonary hypertension. The diagnosis is based on
hemodynamic characterization including the evaluation of cardiac
output and pulmonary vascular resistance on right heart catheter-
ization. This disease has prognostic relevance for LT and is detected
between 2% and 14% of patients with cirrhosis [52–56]. Based on
the mean pulmonary artery pressure, portopulmonary hyperten-
sion can be graded into mild (MPAPP25 to <35 mm Hg), moder-
ate (MPAPP35 to <45 mm Hg), and severe (MPAPP45–50 mm
Hg). Patients with moderate or severe portopulmonary hyperten-
sion have increased transplantation relatedmortality [57], and, for
this reason, LT is contraindicated in these patients if they do not
respond to medical therapy [58]. Patients with moderate and
severe portopulmonary hypertension may beneﬁt from treatment
[59–65], although randomized clinical trials are lacking. The ben-
eﬁt of administering prophylactic beta-blockers to prevent portal
hypertension related bleeding should be evaluated on an individ-
ual basis, as suggested by one study that showed that the removal
of betablockers leads to a decrease in pulmonary vascular resis-
tance and an increase in exercise capacity [66].
Cardiac disease in LT candidates: coronary artery disease (CAD)
Historically, patients with end-stage liver disease were consid-
ered to be relatively well protected from CAD due to their char-
acteristic hemodynamic proﬁle and decreased cholesterol levels
[67]. However, recent studies suggest that CAD is possibly more
frequent in cirrhotic patients than in the general population.
The prevalence of CAD in LT candidates over the age of 45–
50 years ranges between 6% and 26% [68–70], depending on the
selection criteria. Silent moderate to severe CAD has been
detected in 13.3% in a large study [68], and therefore, it should
be actively screened for in high-risk patients. Patients with more
than one cardiovascular disease risk factor such as male sex,
age >50 years, smoking, hypercholesterolemia, and diabetes mel-
litus, have a greater probability of concomitant signiﬁcant CAD
[70]. Special care should be taken in patients with diabetes mel-
litus, as this disease has been associated with the presence of
asymptomatic CAD [68], and the combination of diabetes and
CAD has a very poor prognosis after LT [71]. Furthermore, as
previously mentioned, patients with cirrhosis due to NAFLD or
alcoholic liver disease may have an increased risk of CAD
[12,13,21–24] and perhaps should also be screened. Although
the efﬁcacy of CAD screening in LT candidates has been ques-
tioned, taking into account the clinical burden this implies [72]
most specialists and the present guidelines recommend CAD
screening in selected patients [58].
Management of detected coronary lesions in the pre-transplant
period is an unsolved issue. General recommendations [73,74]
include counseling about weight control, regular physical activity,
smoking cessation, and use of aspirin as well as optimization of
blood pressure, LDL lipoprotein levels (<100 mg/dl), and diabetes
(hemoglobin A1c approximately 7%). However, in the context of
liver cirrhosis some of these recommendations are difﬁcult to
apply or are not applicable. Patients with end-stage liver disease
generally do not have hypertension or elevated LDL-cholesterol
levels, and the use of aspirin can be hampered by thrombocytope-814 Journal of Hepatology 201nia and potential renal toxicity. If indicated, statins can be used
safely and have shown to have beneﬁcial effects on portal pressure
in hemodynamic studies [75]. Percutaneous revascularization can
be performed, but it is unclear whether this intervention may
improve clinical outcome in low-risk asymptomatic patients. Dual
antiplatelet therapy with aspirin and a thienopyridine such as
clopidogrel is always prescribed after coronary stenting. In the
setting of cirrhosis, with thrombopenia and coagulopathy, the
risk of life-threatening hemorrhage related to dual antiplatelet
therapy is a signiﬁcant concern. Furthermore, it is generally rec-
ommended that patients on dual antiplatelet therapy should avoid
surgical procedures, as there is a greater risk for post-operative
bleeding. For these reasons, in the setting of LT candidates, per-
haps bare metal stents are the ideal, as dual antiplatelet therapy
should be administered for a shorter period of time than with
drug-eluting stents. Normally, although a minimum of 1 month
of dual antiplatelet therapy is recommended for bare stents, only
2 weeks of clopidogrel can be given if there is a signiﬁcant increase
in the risk of bleeding [74]. Finally, surgical revascularization has
a very high morbidity and mortality in patients with cirrhosis
[76–80], although some successful cases have been reported [81].
There are relatively fewer reports regarding the relevance of
other common cardiac diseases in liver transplant recipients such
as patent foramen ovale, arrythmias and valvular disease. A small
retrospective study evaluating the inﬂuence of aymptomatic pat-
ent foramen ovale in liver transplant recipients observed a non-
signiﬁcant greater incidence of reperfusion syndrome, and a
slightly longer stay in ICU in these patients compared to age, gen-
der and cause of liver disease matched controls. Neither differ-
ences in morbidity nor mortality was observed [82]. The
presence of valvular dysfunction has been associated to a greater
requirement of vasoactive drugs and blood transfusion in the per-
ioperative period [83]. Patients with end-stage liver disease who
require cardiac valvular surgery are challenging as preLT cardiac
surgery has high morbidity and mortality [80]. Some cases of suc-
cessful simultaneous cardiac surgery and liver transplant have
been reported [84,85], although morbidity and mortality of this
double surgical procedure is most likely increased.
Cardiac evaluation in LT candidates
The outcome of liver transplant depends partially on the co-mor-
bid conditions of the receptor, including the presence of heart
disease [86]. The evaluation of the heart function in the LT candi-
date and the identiﬁcation of high risk patients are both of
utmost importance as cardiovascular complications are a leading
cause of non-graft related death in the post-transplant period
[34,87]. Symptoms of heart disease may be evident in some cases
with ﬂorid clinical expression including pulmonary and periphe-
ral edema, although these ﬁndings are not pathognomonic, par-
ticularly in the context of cirrhosis. However, other more subtle
symptoms can also reﬂect chronic heart failure such as a decrease
in exercise capacity or in oxygen consumption. Several tools such
as the New York Heart Association (NYHA) or Framingham score
[88] may be useful to identify patients with heart failure,
although the clinical applicability in patients with cirrhosis may
be reduced. Cardiac evaluation with electrocardiography (EKG)
and echocardiography is done on a routine basis in most centers
[58]. The decision for further evaluation depends on the individ-
ual characteristics and the LT center. A simpliﬁed algorithm for
cardiac evaluation is shown in Fig. 2.1 vol. 54 j 810–822
Fig. 2. Algorithm for pretransplant cardiac evaluation, taking into account the most frequently identiﬁed problem in LT candidates. Most centers perform EKG and
echocardiography on a routine basis. Screening of patients with risk factors for CAD is also recommended. According to the ﬁndings in these initial examinations, further
tests will be performed.
JOURNAL OF HEPATOLOGYAbsolute and relative cardiac contraindications for LT are dif-
ﬁcult to establish as clinical practice varies between centers and
as this decision is taken on an individual basis. When evaluating a
patient, both the perioperative risk attributable to pre-existing
cardiac disease and the risk associated with the long-term out-
come of this disease must be considered. Patients with overt
heart failure due to cardiac disease will most likely not beneﬁt
from LT. Also, there is general agreement that patients who have
moderate or severe portopulmonary hypertension should not be
considered for LT unless a clinical and hemodynamic response is
achieved after vasodilator therapy [59,62–64]. Prognostic signiﬁ-
cance of cirrhotic cardiomyopathy remains to be determined.
There are no clear recommendations about the management of
CAD in LT candidates. It has been suggested that diabetic patients
with CAD that is not amenable to revascularization or those
patients with left ventricular dysfunction should be denied LT
[89]. Patients who are ﬁnally accepted as LT candidates will ben-
eﬁt from a healthy lifestyle including a healthy diet and regular
physical exercise.
Electrocardiography
EKG is part of the routine evaluation of the heart in LT candidates
[58]. QT interval prolongation is a characteristic EKG abnormality
in patients with end-stage liver disease [41–45,90]. As discussedJournal of Hepatology 201previously, this electrophysiological abnormality is one of the
typical features of cirrhotic cardiomyopathy.
Ultrasonography
(1) Echocardiography: this technique is helpful to detect struc-
tural and functional heart abnormalities that could inﬂuence
the outcome of the LT and should be done on a routine basis.
Many subtle changes in cardiac morphology have been described
using this technique, including an increase in left and right ven-
tricular cavity size, as well as an increased thickness of the left
ventricle wall [91–95]. Additionally, if tricuspid regurgitation is
detected, right ventricle systolic pressure or pulmonary artery
pressure can be estimated with Doppler echocardiography.
Patients who have a RVSPP 50 mm Hg (an arbitrary standard
cut-off) will require further tests to characterize pulmonary pres-
sure. Although estimation of pulmonary pressure is less precise
with higher values of mean pulmonary artery pressure [56,96],
this technique can identify patients with moderate or severe por-
topulmonary hypertension with relative accuracy [56] as it has a
high negative predictive value [55]. Finally, although not speciﬁ-
cally a cardiac disease, the presence of hepatopulmonary syn-
drome is also evaluated by echocardiography in patients with
clinical suspicion due to the presence of hypoxemia [97]. If there
are doubts regarding the possible presence of intra-atrial com-1 vol. 54 j 810–822 815
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munication, transesophageal echocardiography should be per-
formed. Although no studies have evaluated this speciﬁcally,
once the patient is on the waiting list, it seems reasonable to
repeat an echocardiogram on a yearly basis or whenever indi-
cated if novel symptoms develop.
(2) Carotid intima-media thickness: the measurement of carotid
intima-media thickness by ultrasound has been proposed as a
safe and easy-to perform alternative to predict cardiovascular
disease; however, it is mainly used in the research ﬁeld as no
studies have evaluated this measurement in pre-transplant
patients [98].
Cardiac magnetic resonance imaging (MRI)
Cardiac MRI provides a detailed structural and functional evalua-
tion of the heart, as well as tissue characterization. In the setting
of hemochromatosis, cardiac MRI may be useful to evaluate the
degree of iron overload [16]. In patients with familial amyloidosis,
cardiac involvement can be detected by gadolinium enhanced car-
diac MRI with high accuracy [99]. Furthermore, in patients with
known or suspected CAD it can be used to evaluate the presence
of myocardial scars and to identify viablemyocardium susceptible
for functional recovery after an eventual revascularization [100].
Further studies are needed to evaluate the role of cardiac MRI in
the pre-transplant evaluation.
Computed tomography
The coronary artery calciﬁcation score (CACS) as measured by
computerized tomography, has been proposed as an independent
risk factor for CAD in non-cirrhotic patients. A recent study [101]
of 101 cirrhotic patients showed a strong relationship between
the CACS and a number of speciﬁc cardiovascular risk factors.
In this study, the CACS revealed a high prevalence of occult cor-
onary artery disease in patients undergoing LT assessment. How-
ever, further studies are needed in order to establish the clinical
relevance of this score and its safety in patients with end stageTable 3. Advantages and disadvantages of different CAD detecting tests in the conte
should be screened. All diabetic patients with evidence of end-organ damage shoul
816 Journal of Hepatology 201liver disease, especially taking into account that a signiﬁcant pro-
portion of patients have impaired renal function. CACS predicts
better cardiovascular disease than measurement of carotid
intima media thickness by ultrasound in non-cirrhotic patients
[102]. There is no data regarding the value of computed tomogra-
phy coronary angiography in pre-transplant patients with sus-
pected CAD.
Stress tests
Different stress tests have been used as part of the pre-transplant
cardiac work-up (Table 3). By increasing myocardial oxygen
requirements, these tests aim to unveil any subclinical imbal-
ances between supply and demand. When the supply of oxygen
is inadequate, normally due to a stenosis in the coronary arteries,
ischemia will initially be detected with hypoperfusion of the
myocardial tissue and lastly with wall motion abnormalities.
Such alterations are detected with perfusion imaging and echo-
cardiography, respectively. When performing stress tests, it is
important to achieve the target heart rate or heart rate-blood
pressure product in order to obtain conclusive results. Tests that
are used in clinical practice are discussed. Other stress tests with
other drugs (such as terlipressin and metariminol) or volume
challenge still remain in the research ﬁeld.
Exercise stress test
Exercise tests have not been extensively evaluated speciﬁcally in
patients with cirrhosis. As patients with decompensated disease
have a poor functional and exercise capacity, achieving target
heart rates in order to have conclusive results is particularly
difﬁcult.
Dobutamine stress test
The value of the dobutamine stress test has been assessed in sev-
eral studies with controversial results. With this technique, a
stress is induced by the administration of the beta-1-agonist
dobutamine and wall motion abnormalities were detected withxt of LT candidate screening. Patients who have at least 2 risk factors for CAD
d be screened.
1 vol. 54 j 810–822
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echocardiography. Although one study suggested that the dobu-
tamine stress test was a very useful tool for the detection of
CAD [69], other studies have suggested that this method is not
sensitive enough to detect inducible ischemia in this group
of patients [103–107]. In a prospective study [103] including
165 LT candidates undergoing dobutamine echocardiography,
inducible ischemia, left ventricle (LV) dysfunction or signiﬁ-
cant valvular regurgitation was demonstrated in less than 10%;
furthermore, 7% of the patients that ﬁnally underwent LT
(n = 71) had cardiac events, that were not previously predicted.
Similarly, another study showed that previous dobutamine stress
echocardiography did not predict cardiovascular events in
patients undergoing LT [107]. However, in this study the inde-
pendent predictors for cardiovascular events were MELD score
and an inconclusive dobutamine stress test (inability to achieve
more than 85% of the maximum predicted heart rate). On the
contrary, a conclusive negative dobutamine stress test (no induc-
ible ischemia observed despite achieving an appropriate heart
rate or heart rate-blood pressure product) had a high negative
predictive value [107].
Due to chronotropic incompetence and frequent use of betab-
lockers, between 26% and 56% of dobutamine stress test studies
in patients with cirrhosis are inconclusive studies because target
heart rates and/or heart rate-blood pressure products were not
achieved [105–108]. One study using dobutamine stress myocar-
dial contrast perfusion echocardiography suggested that this tool
may be more useful in the evaluation of patients with advanced
liver disease [109], but currently this technique remains only in
the research ﬁeld.
Nuclear myocardial perfusion imaging
Nuclear myocardial perfusion imaging with the administration of
vasodilator drugs (such as adenosine or dipyridamole) has also
demonstrated controversial results. This is possibly related to
the challenges of achieving further vasodilatation in patients
with a very low systemic vascular resistance at baseline
[104,110–112].
Cardiac catheterization
Right heart catheterization
According to current guidelines, when pulmonary hypertension is
suspected (RVSP >50 mmHg) right heart catheterization should be
performed in order to conﬁrm the diagnosis and characterize the
pressure-resistance relationship in the pulmonary artery [56,97].
Diagnosis of portopulmonary hypertension is established by the
measurement of mean pulmonary artery pressure (MPAP >25 mm
Hg) and pulmonary vascular resistance (>240 dynseccm5) and/
or pulmonary capillary wedged pressure (<15 mm Hg). Hemody-
namic characterization of pulmonary hypertension will allow
one to distinguish portopulmonary hypertension from pulmonary
venous hypertension. According to mean pulmonary artery pres-
sure, portopulmonary hypertension is graded as has been previ-
ously described. Acute response to inhaled or intravenous
vasodilators may help identify patients who could beneﬁt from
treatment and thereafter proceed to LT, although this strategy
has not been speciﬁcally evaluated [113–116].
Coronary angiography
There is consensus about the need to perform additional test-
ing to evaluate the presence of signiﬁcant CAD in patientsJournal of Hepatology 201who have more than one cardiovascular risk factor [58], how-
ever there are no recommendations about which test should be
done. Coronary angiography is the gold standard technique to
evaluate the presence of CAD. Although it has a low rate of
complications [117] and can allow therapeutic management
of the coronary lesion, it is an invasive test, that requires poten-
tially nephrotoxic contrast media, and no information regarding
the functional behavior of the coronary artery stenosis is
obtained.
Cardiopulmonary exercise testing
Several studies have demonstrated that patients with cirrhosis
have a reduced aerobic capacity, which has been partially attrib-
uted to cirrhotic cardiomyopathy [118–120]. A study has
described an association between aerobic capacity and 100-day
survival after liver transplantation [121]. Although, it may pro-
vide interesting information, most centers do not use this method
on a regular basis for evaluation of LT candidates.Relationship between the heart and the liver during LT
LT is a signiﬁcant cardiovascular stressor for the patient with
cirrhosis, as it results in important changes in preload and
afterload, and the sudden release of cytokines and vasoactive
mediators into the systemic circulation. The greatest impair-
ment of hemodynamic stability occurs during the clamping of
the hepatic vein (which involves a considerable reduction of
the amount of blood that reaches the heart) and, especially,
at the time of reperfusion [5]. Post-reperfusion syndrome is
deﬁned by a drop of mean arterial blood pressure at least
30% from baseline for at least 1 min in the ﬁrst 5 min after
reperfusion [5]. Although the mechanisms involved in the
development of this syndrome have not been fully character-
ized, it is attributed to the liberation of cytokines and cardiode-
pressive substances [122], and has been associated with high
baseline levels of proinﬂammatory cytokines such as IL-6 [4].
It is not well established whether or not previous heart function
has a role in its development.
A number of studies have suggested that a subset of patients
show an abnormal cardiac response during LT. The intraopera-
tive hemodynamic behavior of 209 patients undergoing LT for
end-stage liver disease or hepatocellular carcinoma was recently
evaluated by continuous monitoring of right-heart pressure [6].
Twenty-three percent of the patients had an abnormal cardiac
response deﬁned by a decrease in stroke work despite an increase
in preload, measured by the pulmonary wedge capillary pressure.
Patients who developed this behavior seemed to have a greater
circulatory dysfunction, with lower central venous pressure
and hyponatremia. Additionally, this abnormal cardiac response
during LT was associated with a longer post-operative tracheal
intubation time [6] Similarly, abnormal hemodynamic behavior
deﬁned by low MAP (<40 mm Hg) or high MPAP (>40 mm Hg)
has been associated to negative surgical outcome deﬁned by
the presence of poor early graft function, primary graft non-
function and death due to hemodynamic causes [123]. On the
other hand, other studies that evaluated parameters obtained
by transesophageal echocardiography suggest that alterations in
cardiac contractility play only a minor role in the hemodynamics
of LT [124,125].1 vol. 54 j 810–822 817
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Incidence of cardiovascular events in the post-transplant period
Different retrospective studies have evaluated the incidence of
cardiovascular events in the post-transplant period. A retrospec-
tive study [87] of 146 liver transplants demonstrated a 3.4% rate
of major cardiovascular events (deﬁned by the presence of myo-
cardial infarction, reversible ischemia, pulmonary edema, cardio-
genic shock, symptomatic rhythm disturbances and pulmonary
embolism) intra-operatively and a 23% rate during the ﬁrst
6 months. Interestingly, the presence of major cardiac events
was associated with a lower 5-year survival rate. Another retro-
spective study [34] which included 86 patients in whom pre-
transplant heart disease was ruled out, detected a 7% prevalence
of heart failure after LT. However, it should be underlined that
pulmonary oedema may be secondary to volume overload and
renal failure. Similarly, a 10% incidence of severe adverse cardio-
vascular events (myocardial infarction, new heart failure, asystole
or unstable ventricular arrhythmia requiring acute treatment)
during surgery and up to the ﬁrst 4 months was described in a
non-selected group of LT recipients [107]. A recent retrospective
study evaluated 403 patients to identify the risk factors that
predict cardiac outcomes (deﬁned by a composite end-point of
myocardial infarction or death) in the ﬁrst 30 days after LT sur-
gery. Forty-eight patients (12%) developed the end-point, and
the independent risk factors that were identiﬁed were previous
history of stroke, CAD, post-operative sepsis and increased inter-
ventricular septal thickness, while perioperative use of beta-
blockers was a protective factor of this outcome [126]. Lastly, a
case-control study evaluating the factors associated with severe
left heart failure after LT has shown that the characteristics of this
entity were different according to time of presentation [127].
Immediate post-operative left heart failure had no association
with previous or concurrent events, while a later onset was asso-
ciated with MELD score and the presence of infection. The mor-
tality rate in these patients was very high (45%).
The incidence of post-transplant cardiac events has only been
determined prospectively in one small study in which 10 out of
40 patients suffered a cardiac event (two intra-operative arrests
and eight clinically signiﬁcant episodes of pulmonary edema)
[50]. The difference in the incidence of these cardiac events
may be due to heterogeneous study populations (Table 1).
Clinical outcome of pre-transplant cardiac disease after LT
Systemic diseases can lead to cirrhosis and heart disease. The
presence of previous cardiovascular disease increases the inci-
dence of major cardiovascular events in the post-transplant
setting. Although there are no studies that speciﬁcally address
the natural history of cardiac disease associated with alcoholic
cardiac disease or hemochromatosis after LT, presumably the
prognosis will depend on the control of the original cause of both
the heart and liver disease. Special effort should be made in order
to provide alcoholic patients the support they need to maintain
abstinence. Patients with hemochromatosis have a lower survival
rate than other etiologies of liver disease, attributed to cardiac
complications and infections [20]. Iron overload may recur in
the postransplant period [19]. In this situation, in absence of
speciﬁc studies, it seems reasonable to initiate iron depletion818 Journal of Hepatology 201therapy. The metabolic syndrome is a relevant problem in the
post LT setting, and this problem is enhanced in patients with
pre-existing disease. These patients will require additional sup-
port and treatment in order to minimize their cardiovascular risk.
Finally, after LT in familial amyloid polyneuropathy, once the
metabolic defect is solved, the patient’s neurological condition
should at least stabilize. In studies that evaluated the cardiac out-
come in patients who were transplanted for this disease, sympa-
thetic cardiac denervation remained stable, but cardiac amyloid
inﬁltration progressed [26,128,129].Speciﬁc cardiac diseases in cirrhosis
(1) Hemodynamic changes in cirrhosis: 2 weeks after LT, car-
diac output was reported to decrease in parallel with an increase
in systemic vascular resistance and the normalization of portal
hypertension [130,131]. Furthermore, at 2 months after LT, a fur-
ther increase of systemic vascular resistance has been observed
without changes in cardiac output [131]. Pre-transplant hemody-
namic changes in Child-Pugh class A patients are less pro-
nounced, so the normalization of hemodynamic parameters
could be achieved earlier in these patients.
(2) Cirrhotic cardiomyopathy: two prospective studies have
evaluated the natural history of cirrhotic cardiomyopathy after
LT. In the ﬁrst study, 40 patients were followed up for 3 months
after LT [50] and the deterioration of diastolic function as mea-
sured by echocardiography was observed. The second study also
evaluated 40 patients with echocardiography and stress radionu-
clide ventriculography [132], with repeat measurements
6 months after transplantation in 15 patients, and showed an
improvement in wall thickness, in diastolic function and in sys-
tolic response and exercise capacity during stress. These diver-
gent results may simply be due to the different time frame in
which they were performed [133]. In addition, echocardiographic
indices may be difﬁcult to interpret given the changes in load
after LT [32,33]. Improvement of electrophysiological abnormali-
ties with a decrease in QT interval has been observed at 3 months
after LT [46]. Far from being solved, the debate remains open. A
recent case report describes an immediate intra-operative recov-
ery of diastolic function suggesting underlying a metabolic inhi-
bition of myocardial metabolism [134]. Further studies will be
needed to establish the natural history of this entity.
(3) Portopulmonary hypertension: in most LT centers, patients
with moderate or severe portopulmonary hypertension are not
transplanted, unless they achieve an appropriate hemodynamic
response with treatment. Observational studies have reported
satisfactory outcomes with this approach [60]. Vasodilators
should be maintained until hemodynamic impairment is
resolved; normally approximately 6 months after LT. Patients
with portopulmonary hypertension have a trend to have an
increased requirement for ventilation and longer ICU stay [135].
(4) Cardiac disease in LT candidates: coronary artery disease
(CAD): a retrospective review of the outcomes after LT has been
reported in 32 patients with pre-existing CAD [136]. Of these
32 patients, CAD was managed medically in 9 patients, by percu-
taneous coronary intervention in one patient and surgically in 22
patients. Both the medically and surgically managed patients had
approximately a 50% mortality rate at 3 years after LT. The
patient who had been managed with angioplasty was alive at
the end of follow-up. Currently, patients with pre-existing coro-
nary artery disease should be evaluated on an individual basis
while further studies are awaited.1 vol. 54 j 810–822
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De novo presentation of cardiac disease in the post-transplant
period.
One of the most relevant problems in the post-transplant per-
iod is the increased cardiovascular disease risk. With improve-
ment in long-term survival of LT recipients, the long-term
effects of immunosuppression, such as hypertension, type 2 dia-
betes, dyslipemia, and obesity, increases the risk of cardiovascu-
lar disease. Interestingly, the prevalence of metabolic syndrome
in LT recipients has been recently reported between 43% and
58%, which is far greater than the expected 24% estimated for
the age and gender matched population [137]. Acute coronary
syndrome and myocardial infarction in patients who had
received LT (n = 118) has an incidence of almost 5% per year
(mean follow-up 58 month), and is more frequent in patients
with metabolic syndrome [138]. Another study, observed a 3-fold
increase in the risk of ischemic cardiac events and a 2.5-fold
increase in the risk of cardiovascular death compared to an
age-matched population [139]. Cardiac muscle protectors, which
are commonly used in postLT such as ACE inhibitors, spirinolac-
tone, beta-blockers and statins may have a beneﬁcial role in this
setting.Conclusions
The heart and the liver have a reciprocal inﬂuence in all phases
of LT. In the pre-transplant period, it is of utmost relevance to
evaluate the heart function of the LT candidate in order to
determine the surgical risks; severe cardiac problems associated
with cardiovascular risk factors should be identiﬁed, along with
the etiology of the liver disease, or with the liver disease on its
own. Furthermore, although the recognition of patients with
silent coronary artery disease is necessary, studies are required
to guide an evidence-based management of these patients. Iden-
tiﬁcation of high-risk patients will help to establish the best
approach for the management of their liver disease, taking into
account cardiovascular risk during the LT surgery and in the
post-transplant period. Even despite a careful selection of
patients, cardiovascular events in the post-transplant period are
frequent. Strict control of cardiovascular risk factors is
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